Nutex Health president buys shares, exercises RSUs

Nutex Health Inc. director and president Warren Hosseinion reported two equity-related moves.

Rhea-AI Filing Summary

Nutex Health Inc. director and president Warren Hosseinion reported two equity-related moves. On March 19, 2026 he made an open-market purchase of 252 shares of common stock at a price of $94.0723 per share, bringing his direct common stock holdings to 7,765 shares.

On March 10, 2026 he also exercised 3,656 restricted stock units into an equivalent number of common shares, a derivative exercise recorded at a conversion price of $0.00 per unit, with 12,465 restricted stock units beneficially owned following that grant. A footnote explains this Form 4 corrects the previously reported RSU balance from an earlier filing for that March 10 transaction.

Insider Trade Summary

Net Buyer: 252 shares

Net Buy 2 txns

Insider Hosseinion Warren

Role President

Bought 252 shs ($24K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	252	$94.0723	$24K
Exercise	Restricted Stock Units	3,656	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 12,465 contracts (Direct); Common Stock — 7,765 shares (Direct)

Footnotes (1)

1. F1. This Form 4 corrects the number of restricted stock units (RSUs) beneficially owned following the RSU grant reported in the reporting person's Form 4 filed on March 11, 2026 relating to a transaction dated March 10, 2026.

FAQ

What insider transactions did Nutex Health (NUTX) report for Warren Hosseinion?

Warren Hosseinion reported an open-market purchase of 252 Nutex Health common shares and a derivative exercise of 3,656 restricted stock units into common stock, both in March 2026, increasing his direct equity exposure in the company.

How many Nutex Health shares did Warren Hosseinion buy on the open market?

He bought 252 Nutex Health common shares in an open-market transaction at $94.0723 per share. After this purchase, his direct common stock holding reported in the filing increased to 7,765 shares, reflecting his updated ownership position.

What happened with Warren Hosseinion’s restricted stock units at Nutex Health?

He exercised 3,656 restricted stock units into the same number of Nutex Health common shares at a stated conversion price of $0.00. Following this RSU grant and correction, the filing reports that he beneficially owned 12,465 restricted stock units.

Why does the Nutex Health Form 4 mention a correction to RSU holdings?

A footnote states that this Form 4 corrects the number of restricted stock units beneficially owned after the March 10, 2026 RSU grant. It revises figures previously reported in a Form 4 filed on March 11, 2026 for that same RSU transaction.

Is Warren Hosseinion’s Nutex Health stock ownership direct or indirect?

The filing classifies his ownership as direct, with the code “D” for both the common stock and the restricted stock unit transactions. No indirect ownership entities or special ownership structures are referenced in the provided transaction details or footnotes.

What is the overall direction of Warren Hosseinion’s recent Nutex Health insider activity?

The reported activity is net-buy. He made an open-market purchase of common shares and exercised restricted stock units into additional common stock, with no sales or dispositions recorded in the summarized March 2026 transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 01:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hosseinion Warren

(Last) (First) (Middle)

1776 YORKTOWN STREET

C/O NUTEX HEALTH INC.

(Street)

HOUSTON TEXAS 77056

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nutex Health Inc. [ NUTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		P		252	A	$94.0723	7,765	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units(1)	$0	03/10/2026		M		3,656		03/01/2027	03/01/2029	Common Stock	3,656	$0	12,465(1)	D

Explanation of Responses:

1. This Form 4 corrects the number of restricted stock units (RSUs) beneficially owned following the RSU grant reported in the reporting person's Form 4 filed on March 11, 2026 relating to a transaction dated March 10, 2026.

	/s/ Warren Hosseinion	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)